Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Elford

Showing results (51-60 of 63) with videos related to

Pageof 7
Sort By:
British Journal of Cancer|July 1, 1988
A phase 1 and pharmacokinetic study of didox: a ribonucleotide reductase inhibitorD Veale, J Carmichael, B M Cantwell, et al.
Biochemical Pharmacology|July 31, 2002
Trimidox, an inhibitor of ribonucleotide reductase, synergistically enhances the inhibition of colony formation by Ara-C in HL-60 human promyelocytic leukemia cellsMonika Fritzer-Szekeres, Alexandra Salamon, Michael Grusch, et al.
Antiviral Research|May 8, 2004
In vivo examination of hydroxyurea and the novel ribonucleotide reductase inhibitors trimidox and didox in combination with the reverse transcriptase inhibitor abacavir: suppression of retrovirus-induced immunodeficiency diseaseL Ryan Sumpter, Mohammed S Inayat, Erin E Yost, et al.
Experimental Hematology|May 30, 2001
Activation of caspases and induction of apoptosis by novel ribonucleotide reductase inhibitors amidox and didoxM Grusch, M Fritzer-Szekeres, G Fuhrmann, et al.
Antiviral Research|October 9, 2002
Suppression of retrovirus-induced immunodeficiency disease (murine AIDS) by trimidox and didox: novel ribonucleotide reductase inhibitors with less bone marrow toxicity than hydroxyureaChristopher N Mayhew, Leseilane J Mampuru, Damodoran Chendil, et al.
British Journal of Cancer|March 1, 1990
A phase I and pharmacokinetic study of didox administered by 36 hour infusion. The Cancer Research Campaign Phase I/II Clinical Trials CommitteeJ Carmichael, B M Cantwell, K A Mannix, et al.
Cancer Letters|February 21, 2006
Gallic acid inhibits ribonucleotide reductase and cyclooxygenases in human HL-60 promyelocytic leukemia cellsSibylle Madlener, Christoph Illmer, Zsuzsanna Horvath, et al.
Antiviral Therapy|December 14, 2011
Paradoxical response to prophylactic Didox (N-3, 4 trihydroxybenzamide) treatment in murine cytomegalovirus-infected miceVera Go, Yajarayma J Tang-Feldman, Stephanie R Lochhead, et al.
Cellular Immunology|July 29, 2017
Didox (3,4-dihydroxybenzohydroxamic acid) suppresses IL-33-induced cytokine production in primary mouse mast cellsHeather L Caslin, Jamie Josephine Avila McLeod, Andrew J Spence, et al.
Blood Cells, Molecules & Diseases|January 24, 2020
Didox (3,4-dihydroxybenzohydroxamic acid) reduces the vascular inflammation induced by acute intravascular hemolysisJuliete A F Silva, Érica M F Gotardo, Hanan Chweih, et al.
Pageof 7

Showing results (51-60 of 63) with videos related to

Sort By:
Pageof 7
British Journal of Cancer|July 1, 1988
A phase 1 and pharmacokinetic study of didox: a ribonucleotide reductase inhibitorD Veale, J Carmichael, B M Cantwell, et al.
Biochemical Pharmacology|July 31, 2002
Trimidox, an inhibitor of ribonucleotide reductase, synergistically enhances the inhibition of colony formation by Ara-C in HL-60 human promyelocytic leukemia cellsMonika Fritzer-Szekeres, Alexandra Salamon, Michael Grusch, et al.
Antiviral Research|May 8, 2004
In vivo examination of hydroxyurea and the novel ribonucleotide reductase inhibitors trimidox and didox in combination with the reverse transcriptase inhibitor abacavir: suppression of retrovirus-induced immunodeficiency diseaseL Ryan Sumpter, Mohammed S Inayat, Erin E Yost, et al.
Experimental Hematology|May 30, 2001
Activation of caspases and induction of apoptosis by novel ribonucleotide reductase inhibitors amidox and didoxM Grusch, M Fritzer-Szekeres, G Fuhrmann, et al.
Antiviral Research|October 9, 2002
Suppression of retrovirus-induced immunodeficiency disease (murine AIDS) by trimidox and didox: novel ribonucleotide reductase inhibitors with less bone marrow toxicity than hydroxyureaChristopher N Mayhew, Leseilane J Mampuru, Damodoran Chendil, et al.
British Journal of Cancer|March 1, 1990
A phase I and pharmacokinetic study of didox administered by 36 hour infusion. The Cancer Research Campaign Phase I/II Clinical Trials CommitteeJ Carmichael, B M Cantwell, K A Mannix, et al.
Cancer Letters|February 21, 2006
Gallic acid inhibits ribonucleotide reductase and cyclooxygenases in human HL-60 promyelocytic leukemia cellsSibylle Madlener, Christoph Illmer, Zsuzsanna Horvath, et al.
Antiviral Therapy|December 14, 2011
Paradoxical response to prophylactic Didox (N-3, 4 trihydroxybenzamide) treatment in murine cytomegalovirus-infected miceVera Go, Yajarayma J Tang-Feldman, Stephanie R Lochhead, et al.
Cellular Immunology|July 29, 2017
Didox (3,4-dihydroxybenzohydroxamic acid) suppresses IL-33-induced cytokine production in primary mouse mast cellsHeather L Caslin, Jamie Josephine Avila McLeod, Andrew J Spence, et al.
Blood Cells, Molecules & Diseases|January 24, 2020
Didox (3,4-dihydroxybenzohydroxamic acid) reduces the vascular inflammation induced by acute intravascular hemolysisJuliete A F Silva, Érica M F Gotardo, Hanan Chweih, et al.
Pageof 7